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Abstract 
Paralytic ileus is a severe complication
resulting from a variety of disorders. It occurs
most commonly in patients with serious under-
lying medical or surgical conditions. Prompt
diagnosis and appropriate management may
improve the outcome. We describe 2 cases of
onco-hematologic patients who presented this
complication after intensive chemotherapy.
Introduction
Paralytic ileus is a gastrointestinal motility
disorder. It is rare in childhood, but severe
complications result from a variety of disor-
ders.1,2 This condition results in colonic atony
deriving from an imbalance in autonomic
bowel innervation. Patients with trauma, elec-
trolyte disturbances, medications affecting
gastrointestinal motility and sepsis, are pre-
disposed to its development. The principal
ileus symptoms are abdominal pain and dis-
tention, constipation, failure to pass gas or
stool, and vomiting. Diagnosis is based on clin-
ical presentation with X-ray evidence of
marked colonic dilatation in the absence of a
mechanical obstruction. Without treatment,
the patient’s general conditions rapidly worsen
until dehydration and shock.
We describe 2 cases of onco-hematologic
patients who presented this acute complica-
tion after intensive chemotherapy.
Case #1
VG is a 5-year old girl with a non-Hodgkin’s
abdominal lymphoma which was diagnosed in
March 2011 by abdominal surgery for intestin-
al invagination. She was enrolled on the AIEOP
(Italian Association of Pediatric Hematology
Oncology) LNH 97 protocol. At the end of a
chemotherapy cycle, in disease remission, she
developed severe abdominal pain and disten-
sion with constipation, vomiting, and fever.
Blood tests showed an increase in absolute
leukocyte number and C-reactive protein.
Intestinal pseudo-obstruction was confirmed
both clinically and by X-ray (Figure 1). Broad-
spectrum antibiotic therapy (meropenem,
metronidazole, vancomicin, fluconazol), a
nasogastric decompression and parenteral
nutrition were performed. However, two days
later, her general condition worsened with
aplasia (PMN 130/mmc), severe abdominal
pain, distension, hyponatremia and fever.
Therapy with G-CSF was started. An abdominal
computed tomography scan (CT) revealed sig-
nificant cecal dilatation without mechanical
obstruction with residual fecal loading.
Therefore, four days after the end of
chemotherapy, she underwent surgery with an
intestinal resection for ileitis with a pseudo-
volvolus. Ileostomy was not performed because
important mucosal damage made surgery
impossible. The hystological examination was
negative for the baseline disease. Cultural
specimens were negative. Only urine culture
was positive for E. coli ESBL positive. Her gen-
eral condition gradually improved over the fol-
lowing days. Supportive therapy was, there-
fore, continued. 
Six days after surgery, her condition wors-
ened again with fever, desaturation and gastric
pain. Chest X-ray showed a bilateral pleural
effusion. The girl was transferred to the inten-
sive care unit with invasive ventilation sup-
port. Antibiotic therapy was changed with col-
imicina, cefepime and linezolid. Her general
condition was still poor. Maternal leukocyte
infusion was carried out. Over the following
days, her clinical condition improved. Six days
later, she was extubated with no recurrent
abdominal pain or fever and normal leukocyte
count. Enteral nutrition was gradually restart-
ed without any complications. She presented
regular bowel function. Five days later, 32 days
after onset, she was discharged from hospital
in good general condition. 
She continued the chemotherapy protocol
until July 2011. She is now in good general
condition in complete disease remission. 
Case #2
GM was diagnosed at the age of 18 with a B-
cell acute lymphoblastic leukemia (ALL), cen-
tral nervous system (CNS) negative, one
month after traumatic abdominal injuries due
to a car accident. He started treatment accord-
ing to the AIEOP LLA R 2006 protocol with good
disease response (blasts<1000/UL) after eight
days. 
Induction therapy was immediately compli-
cated by asthenia, nausea, and constipation
treated with antiemetic, oral laxatives and rec-
tal enemas with transient relief. After 3 doses
of VCR (vincristine), he developed severe
abdominal pain with marked constipation
associated with weight loss. X-ray of the
abdomen showed gas/fluid-levels scattered
throughout the abdomen. Blood count showed
pancytopenia (PMN 90/mmc). Parenteral ther-
apy was started with hydratation, antibiotics
(piperacilline/tazobactam, amikacine) and
antifungal (fluconazol). Rectal enemas still
had transient relief. Stool cultural examina-
tions were negative, C-reactive protein was
slightly raised.
Five days later he presented severe abdomi-
nal and left scapular pain with nausea, vomit-
ing and fever. Physical examination showed
abdominal distention. The X-ray of the
abdomen showed free gas in the abdominal
cavity (left hypochondrium). According the
suspicious of intestinal perforation due to par-
alitic ileus and mucositis, the patient under-
went emergency surgery. Perforations in the
ileo cecal valve and cecum end were found and
repaired, associated with an important dilata-
tion in the proximal ileus and a temporary
ileostomy was needed. The peritoneal culture
was positive for Enterococcus faecalis and
Prevotella oralis.
After surgery, the leukocyte count increased
and the patient’s condition improved. Broad-
spectrum antibiotics (meropenem, van-
comicin, metronidazole), antifungal therapy
(fluconazol), and continuous hydration with
close monitoring of electrolytes were contin-
ued. He was transferred to the Pediatric Onco-
Hematology Division 12 days after surgery. At
Day 46 a bone marrow showed the remission
of disease. On Day 58, after an improvement in
his general clinical condition, chemotherapy
was restarted. 
Enteral nutrition was gradually restarted
and bowel function reestablished. He was dis-
charged from hospital two weeks later with
ileostomy. He is now in good clinical condition
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in complete disease remission and is continu-
ing chemotherapy.
Discussion 
Paralytic ileus is associated with infections
or disorders of autonomic neuropathy caused
by chemotherapy drugs, such as vincristine
and vinblastine or opioid, which depress bowel
peristalsis. 
VCR gastrointestinal toxicity seems to be
dose-related and cumulative.3 Co-administra-
tion of several drugs which interfere with VCR
metabolism and elimination can increase
drug-related toxicity.2,4,5 VCR is metabolized by
the hepatic CYP3A subfamily of enzymes and
then mainly eliminated by biliary excretion.
Several polymorphisms of CYP3A5 with vari-
able phenotypic expression have been
described and might be of importance when
considering the potential implication of drug
interactions. According to this genetic variabil-
ity, in some patients, several drugs, such as
azole antifungals or nifedipine might increase
VCR exposure. Macrolides and steroids have
also been mentioned as interfering with VCR
metabolism, as either inhibitors, inducers, or
both.2,5
However, in pediatric patients, VCR-related
pseudo-obstruction seems to be reversible and
even allows chemotherapy to be continued.
The implications of genetic polymorphisms in
the CYP3A and MDR1 genes are not clear or
feasible in all patients.6
There is little awareness of this condition
and a lack of guidance for both diagnosis and
management. Prompt diagnosis and appropri-
ate management of these patients may reduce
the significant morbidity and mortality seen in
this uncommon condition. The outcome of
ileus varies depending on its cause.1 Initial
management is conservative with bowel rest
and nasogastric decompression, intravenous
fluids and correction of electrolyte imbalance,
cessation of medications affecting colonic
motility.1,7 Especially in onco-hematologic
patients the prompt treatment with broad spec-
trum antibiotics and antifungals is recom-
mended to improve the outcome.
Surgical intervention to remove the cause of
ileus is necessary when the obstruction is
complete or the bowel is likely to become gan-
grenous. The type of surgical procedure
depends on the condition of the bowel and the
cause of the obstruction. In some cases,
ileostomy or colostomy, either temporary or
permanent, may be necessary.1,7
Here we describe 2 oncologic pediatric cases
who developed acute colonic pseudo-obstruc-
tion during intensive chemotherapy. Both
patients underwent intensive chemotherapy
cycles with damage to gut mucoses, and alter-
ations in bowel function during a prolonged
bone marrow depression. While in the first case
the previous surgery was a relevant risk factor,
in the second case the high-dose steroid thera-
py caused concomitant gastric mucose damage
and abdominal distension associated with a
bowel atony due to VCR. Genetic polymorphisms
were not assessed in our patients. In both cases,
the prompt therapy with intravenous fluid,
nasogastric decompression and antibiotic ther-
apy improved the outcome, although both
patients needed a multidisciplinary approach
with surgery, carefully controlled electrolytic
imbalance and sepsis status.
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Case Report
Figure 1. Intestinal pseudo-obstruction confirmed by X-ray.
